Santhera Pharmaceuticals has declared that its drug, AGAMREE® (vamorolone), has received authorization within the European Union to be prescribed for those diagnosed with Duchenne muscular dystrophy.

InnoCare Pharma has announced that their phase II trial of the novel TYK2 inhibitor ICP-332 met its primary endpoint in treating adults with moderate to severe atopic dermatitis.

NOS inhibitors are drugs that inhibit nitric oxide synthase, an enzyme crucial in various physiological processes.

Drug combinations can improve drug resistance by targeting multiple pathways or mechanisms simultaneously, making it more difficult for the cancer cells to develop resistance.

Caliway Finalizes Funding Round Exceeding Targets, Locks in Excess of $100M for Critical Phase 3 Trial of CBL-514 for Subcutaneous Fat Reduction.

The combination of multiple drugs can have significant effects on drug delivery.

VMAT2 inhibitors are drugs that target and inhibit the vesicular monoamine transporter 2 protein, crucial in neurotransmitter regulation.

Transdermal drug delivery is a method of delivering medication through the skin to achieve systemic effects.

Wave Life Sciences has commenced the Phase 2 FORWARD-53 study, beginning treatment with WVE-N531 for individuals with Duchenne Muscular Dystrophy.

Cannabinoids can be categorized into three types based on their origin: endocannabinoids, phytocannabinoids, and synthetic cannabinoids.

VEGF inhibitors are drugs that block the activity of vascular endothelial growth factor, crucial in angiogenesis.

On 2 Dec 2023, the latest clinical trial about TQB2450 for the treatment for patients with hepatocellular carcinoma at high risk of recurrence was presented in 2023 ESMO_ASIA.